Rapid Detection of Airway Pathogens for Lung Transplantation

Sponsor
University of California, San Francisco (Other)
Overall Status
Completed
CT.gov ID
NCT03933878
Collaborator
BioFire Diagnostics, LLC (Industry)
200
1
23.6
8.5

Study Details

Study Description

Brief Summary

Pneumonias and lower respiratory tract infections can have important long-term consequences, particularly in the context of lung transplantation, where pneumonia is a major cause of death. Candidate organs and lung transplant recipients undergo bronchoscopic inspection to assess for lower respiratory tract infection, but traditional culture methods take time, leading to increased risk from inappropriate therapy. The investigators hypothesize that the rapid detection of lower respiratory tract infection, using a semi-quantitative multiplex molecular assay, can decrease the time to appropriate clinical decision making.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Before and after lung transplantation, clinical decision-making for infection diagnosis can be delayed by the time requirements of traditional culture techniques. This study will enroll lung transplant donor candidates and recipients undergoing assessment for lower respiratory tract infection by bronchoscopic alveolar lavage (or washing). The investigators will record bronchoscopy time and time to test result and clinical management decision based on traditional culture methods. The investigators will perform a semi-quantitative multiplex molecular assay for lower respiratory tract infection using the BioFire Pneumonia Panel and these results will be evaluated by clinicians not directly involved in patient care. Timing and outcome of clinical decision making will be recorded. The investigators will compare the time to result using a paired Student's t-test between traditional and molecular methods. Secondary endpoints include time to clinical decision, postulated changes in clinical decisions, and agreement between methods.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    200 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Rapid Detection of Airway Pathogens for Lung Transplantation
    Actual Study Start Date :
    Mar 19, 2019
    Actual Primary Completion Date :
    Mar 5, 2021
    Actual Study Completion Date :
    Mar 5, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    Post-transplant recipient BAL samples

    No intervention will be administered

    Donor BAL samples

    No intervention will be administered

    Outcome Measures

    Primary Outcome Measures

    1. Time to result [One year]

      The investigators will measure the difference between the time that microbiology results became available using standard of care diagnostics and the time of result from molecular methods.

    Secondary Outcome Measures

    1. Changes in clinical management or treatment [One year]

      The investigators will record clinical management decisions resulting from both the BioFire molecular diagnostic assay and the current standard of care clinical procedures. The study will report the percentage agreement on treatment decisions between the two diagnostic pathways.

    2. Agreement between assays [One year]

      The investigators will record pathogen detection results from both the BioFire molecular diagnostic assay and the current standard of care clinical procedures. The investigators will then report the percentage agreement on pathogen detection between the two diagnostic pathways.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Subjects will be included if subjects are able and willing to provide informed consent for this study as part of an ongoing prospective biorepository and clinical data repository cohort study.

    • Donors can be included as subjects if families provide informed consent.

    Exclusion Criteria:
    • Samples from donor organs will be excluded if the organs are unlikely likely to be used based on review of preliminary data.

    • Post-transplant samples will be excluded if the suspicion for infection is sufficiently low that lavage samples are not sent for microbiologic workup or there is insufficient sample for research.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 UCSF Parnassus San Francisco California United States 94143

    Sponsors and Collaborators

    • University of California, San Francisco
    • BioFire Diagnostics, LLC

    Investigators

    • Principal Investigator: John Greenland, MD, PhD, University of California, San Francisco

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of California, San Francisco
    ClinicalTrials.gov Identifier:
    NCT03933878
    Other Study ID Numbers:
    • P0535801
    First Posted:
    May 1, 2019
    Last Update Posted:
    Mar 18, 2021
    Last Verified:
    Mar 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 18, 2021